Study on the Efficacy of Sofosbuvir and Velpatasvir in the Treatment of Chronic Hepatitis C Liver Fibrosis and Its Influence on Liver Function and Serum Cytokines
Objective To analyze the effects of sofosbuvir and velpatasviron liver function and serum cytokines during chronic hepatitis C(CHC)liver fibrosis treatment.Methods 162 patients with CHC liver fibrosis treated in Zhangye People's Hospital Affiliated to Hexi University from January 2020 to December 2022 were conveniently selected as the study objects,and were divided into two groups according to the random number table method,with 81 cases in each group.The conventional group was given routine treatment such as ribavirin,while the observation group was given sofosbuvir and velpatasvir treatment on the basis of conventional group.The clinical efficacy,liver function indi-cators[total bilirubin(TBIL),alanine aminotransferase(ALT)],and liver fibrosis indicators[hyaluronic acid(HA),lam-inin(LN)],serum cytokines[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and the overall incidence of ad-verse reactions were compared between the two groups.Results The total effective rate of the observation group(96.30%)was higher than that of the conventional group(81.48%),and the difference was statistically significant(χ2=9.000,P=0.003).After treatment,TBIL and ALT in the observation group were lower than those in the conventional group,and the differences were statistically significant(both P<0.05).After treatment,HA and LN in observation group were lower than those in conventional group,and the differences were statistically significant(both P<0.05).Af-ter treatment,the serum levels of TNF-α and IL-6 in observation group were lower than those in conventional group,and the differences were statistically significant(both P<0.05).There was no significant difference in the total inci-dence of adverse reactions between the observation group(4.94%)and the conventional group(6.17%)(χ2=0.118,P=0.732).Conclusion Sofosbuvir can effectively improve liver function and liver fibrosis in CHC patients with liver fi-brosis,reduce the level of serum inflammatory factors,and do not increase the incidence of adverse reactions.The clinical treatment is safe and effective.
Sofosbuvir and velpatasvirChronic hepatitis CLiver fibrosisLiver function
NETL
NSTL
万方数据
